Eli Lilly LLY Other cardiometabolic health — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eli Lilly's other cardiometabolic health — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eli Lilly's other cardiometabolic health — revenue?
- Eli Lilly (LLY) reported other cardiometabolic health — revenue of $905M in Q1 2026.
- How has Eli Lilly's other cardiometabolic health — revenue changed year-over-year?
- Eli Lilly's other cardiometabolic health — revenue decreased by 4.2% year-over-year, from $945M to $905M.
- What is the long-term trend for Eli Lilly's other cardiometabolic health — revenue?
- Over 3 years (2022 to 2025), Eli Lilly's other cardiometabolic health — revenue has grown at a 100.5% compound annual growth rate (CAGR), from $496.9M to $4.01B.
- What does other cardiometabolic health — revenue mean?
- This metric represents the total net sales generated from the company's secondary portfolio of cardiometabolic therapeutic products, excluding primary blockbuster treatments. It captures the revenue stream from established or niche pharmaceutical assets focused on metabolic health and cardiovascular conditions. Monitoring this segment provides insight into the performance of the company's diversified product base within the broader cardiometabolic market.